Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567952 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 436
- Enrollment target
NCT05567952 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 436 participants.
The verdict
NCT05567952, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 436 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound. The study is seeking participants who: * Have completed treatment with nirmatrelvir/ritonavir * Have a rebound in COVID-19 symptoms * Are SARS-CoV-2 (COVID-19) positive All study medications will be taken 2 times a day by mouth for 5 days. The first dose of study medication is taken at the study clinic and the rest at home. We will examine the experiences of people receiving the study medicines to those who do not. This will help us determine if the study medicines are safe and effective. People taking part will be in this study for about 24 weeks. Enrolled participants will need to visit the study clinic at least 8 times during the study.
Interventions
- DRUG nirmatrelvir
- DRUG ritonavir
- DRUG placebo for nirmatrelvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 436 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2024-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05567952
The ClinicalTrials.gov registry entry for NCT05567952 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 436 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nirmatrelvir is the first listed.
NCT05567952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05567952 about?
NCT05567952 is a clinical study titled "A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir". The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound. The study is seeking participants who: * Have completed treatment with nirmatrelvir/ritonavir * Have a rebound in COVID-19 symptoms * Are SARS-CoV-2 (COVID-...
What is the current status of trial NCT05567952?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 436 participants. The study started on 2022-10-19. Estimated completion is 2024-02-09.
What interventions are being tested in trial NCT05567952?
The interventions under investigation include: nirmatrelvir (DRUG), ritonavir (DRUG), placebo for nirmatrelvir (DRUG).
Who is sponsoring clinical trial NCT05567952?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.